Long-term patient outcomes following buprenorphine/naloxone treatment for opioid use disorder: a retrospective analysis in a commercially insured population

References

• Degenhardt L, Charlson F, Mathers B, Hall WD, Flaxman AD, Johns N, Vos T. The global epidemiology and burden of opioid dependence: results from the global burden of disease 2010 study. Addiction. 2014;109:1320–33. doi:10.1111/add.12551.
   PubMed Web of Science ®Google Scholar
• Welty L, Harrison A, Abram K, Olson N, Aaby D, McCoy K. Substance abuse and mental health services administration. (2017). Key substance use and mental health indicators in the United States: results from the 2016 national survey on drug use and health (HHS Publication No. SMA 17-5044, NSDUH Series H-52). Rockville, MD: Center for Behavioral Health Statistics and Quality. Subst Abuse Mental Health Serv Administration Retrieved Coll Health Sci. 2019;106:128.
   Google Scholar
• Birnbaum HG, White AG, Schiller M, Waldman T, Cleveland JM, Roland CL. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med. 2011;12:657–67.doi:10.1111/j.1526-4637.2011.01075.x.
   PubMed Web of Science ®Google Scholar
• Florence C, Luo F, Xu L, Zhou C. The economic burden of prescription opioid overdose, abuse and dependence in the United States, 2013. Med Care. 2016;54:901. doi:10.1097/MLR.0000000000000625.
   PubMed Web of Science ®Google Scholar
• Hansen RN, Oster G, Edelsberg J, Woody GE, Sullivan SD. Economic costs of nonmedical use of prescription opioids. Clin J Pain. 2011;27:194–202. doi:10.1097/AJP.0b013e3181ff04ca.
   PubMed Web of Science ®Google Scholar
• McAdam-Marx C, Roland CL, Cleveland J, Oderda GM. Costs of opioid abuse and misuse determined from a medicaid database. J Pain Palliative Care Pharmacother. 2010;24:5–18. doi:10.3109/15360280903544877.
   PubMedGoogle Scholar
• Oderda GM, Lake J, Rüdell K, Roland CL, Masters ET. Economic burden of prescription opioid misuse and abuse: a systematic review. J Pain Palliative Care Pharmacother. 2015;29:388–400. doi:10.3109/15360288.2015.1101641.
   PubMedGoogle Scholar
• Strassels S.Economic burden of prescription opioid misuse and abuse. J Managed Care Pharm. 2009;15:556–62. doi:10.18553/jmcp.2009.15.7.556.
   Google Scholar
• White AG, Birnbaum HG, Mareva MN, Daher M, Vallow S, Schein J, Katz N. Direct costs of opioid abuse in an insured population in the United States. J Managed Care Pharm. 2005;11:469–79.doi:10.18553/jmcp.2005.11.6.469.
   Google Scholar
• Parran T, Adelman C, Merkin B, Pagano M, Defranco R, Ionescu R, Mace AG. Long-Term outcomes of office-based buprenorphine/naloxone maintenance therapy. Drug Alcohol Depend. 2010;106:56–60. doi:10.1016/j.drugalcdep.2009.07.013.
   PubMed Web of Science ®Google Scholar
• Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, Collins J, Raisch D, Casadonte P, Goldsmith RJ. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349:949–58. doi:10.1056/NEJMoa022164.
   PubMed Web of Science ®Google Scholar
• Barnett PG. Comparison of costs and utilization among buprenorphine and methadone patients. Addiction. 2009;104:982–92. doi:10.1111/j.1360-0443.2009.02539.x.
   PubMed Web of Science ®Google Scholar
• Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;(2): CD002207. doi:10.1002/14651858.CD002207.pub4.
   PubMed Web of Science ®Google Scholar
• Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies—tackling the opioid-overdose epidemic. N Engl J Med. 2014;370:2063–66. doi:10.1056/NEJMp1402780.
   PubMed Web of Science ®Google Scholar
• Johnson RE, McCagh JC. Buprenorphine and naloxone for heroin dependence. Curr Psychiatry Rep. 2000;2:519–26. doi:10.1007/s11920-000-0012-8.
   PubMedGoogle Scholar
• McCance-Katz EF. Office-Based buprenorphine treatment for opioid-dependent patients. Harv Rev Psychiatry. 2004;12:321–38. doi:10.1080/10673220490905688.
   PubMed Web of Science ®Google Scholar
• Lo‐ciganic WH, Gellad WF, Gordon AJ, Cochran G, Zemaitis MA, Cathers T, Kelley D, Donohue JM. Association between trajectories of buprenorphine treatment and emergency department and in‐patient utilization. Addiction. 2016;111:892–902. doi:10.1111/add.13270.
   PubMed Web of Science ®Google Scholar
• Chang H-Y, Daubresse M, Saloner B, Alexander GC. Chronic disease medication adherence after initiation of buprenorphine for opioid use disorder. Med Care. 2019;57:667–72. doi:10.1097/MLR.0000000000001165.
   PubMed Web of Science ®Google Scholar
• Tkacz J, Severt J, Kassed C, Ruetsch C. Clinical differences between opioid abuse classes ameliorated after 1 year of buprenorphine-medication assisted treatment. J Addict Dis. 2012;31:100–11. doi:10.1080/10550887.2012.665729.
   PubMed Web of Science ®Google Scholar
• Larochelle MR, Bernson D, Land T, Stopka TJ, Wang N, Xuan Z, Bagley SM, Liebschutz JM, Walley AY. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med. 2018;169:137–45. doi:10.7326/M17-3107.
   PubMed Web of Science ®Google Scholar
• Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, Ferri M, Pastor-Barriuso R. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ (Clin Res Ed). 2017;357. doi:10.1136/bmj.j1550
   PubMed Web of Science ®Google Scholar
• Williams AR, Samples H, Crystal S, Olfson M. Acute care, prescription opioid use, and overdose following discontinuation of long-term buprenorphine treatment for opioid use disorder. Am J Psychiatry. 2020;177:117–24. doi:10.1176/appi.ajp.2019.19060612.
   PubMed Web of Science ®Google Scholar
• Connery HS, Weiss RD. Discontinuing buprenorphine treatment of opioid use disorder: what do we (not) know?. Am Psychiatric Assoc. 2020;177(2): 104–106. doi:10.1176/appi.ajp.2019.19121245.
   PubMed Web of Science ®Google Scholar
• Kraus ML, Alford DP, Kotz MM, Levounis P, Mandell TW, Meyer M, Salsitz EA, Wetterau N, Wyatt SA. Statement of the American Society of Addiction Medicine Consensus Panel on the use of buprenorphine in office-based treatment of opioid addiction. J Addict Med. 2011;5:254–63. doi:10.1097/ADM.0b013e3182312983.
   PubMed Web of Science ®Google Scholar
• Forum NQ. Behavioral health 2016-2017 final report 2022 [accessed 2022 Feb 1].
   Google Scholar
• Pietras S, Azur M, Brown J. Review of medication-assisted treatment guidelines and measures for opioid and alcohol use [Internet]. Washington (DC): Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation; 2015 Nov 25 [accessed 2020 Mar 6].
   Google Scholar
• Hser YI, Saxon AJ, Huang D, Hasson A, Thomas C, Hillhouse M, Jacobs P, Teruya C, McLaughlin P, Wiest K. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi‐site trial. Addiction. 2014;109:79–87. doi:10.1111/add.12333.
   PubMed Web of Science ®Google Scholar
• Morgan JR, Schackman BR, Leff JA, Linas BP, Walley AY. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. J Subst Abuse Treat. 2018;85:90–96. doi:10.1016/j.jsat.2017.07.001.
   PubMed Web of Science ®Google Scholar
• Saloner B, Daubresse M, Alexander GC.Patterns of buprenorphine-naloxone treatment for opioid use disorder in a multi-state population. Med Care. 2017;55:669. doi:10.1097/MLR.0000000000000727.
   PubMed Web of Science ®Google Scholar
• Shcherbakova N, Tereso G, Spain J, Roose RJ. Treatment persistence among insured patients newly starting buprenorphine/naloxone for opioid use disorder. Ann Pharmacother. 2018;52:405–14. doi:10.1177/1060028017751913.
   PubMed Web of Science ®Google Scholar
• Gryczynski J, Mitchell SG, Jaffe JH, O’-Grady KE, Olsen YK, Schwartz RP.Leaving buprenorphine treatment: patients’ reasons for cessation of care. J Subst Abuse Treat. 2014;46:356–61. doi:10.1016/j.jsat.2013.10.004.
   PubMed Web of Science ®Google Scholar
• Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-Year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet. 2003;361:662–68. doi:10.1016/S0140-6736(03)12600-1.
   PubMed Web of Science ®Google Scholar
• Hasan MM, Noor-E-Alam M, Mohite P, Islam MS, Modestino AS, Peckham AM, … Young GJ. Patterns of patient discontinuation from buprenorphine/naloxone treatment for opioid use disorder: a study of a commercially insured population in Massachusetts. J Subst Abuse Treat. 2021;131:108416.doi:10.1016/j.jsat.2021.108416.
   PubMed Web of Science ®Google Scholar
• Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA. 1992;267:2750–55. doi:10.1001/jama.1992.03480200058024.
   PubMed Web of Science ®Google Scholar
• Liebschutz JM, Crooks D, Herman D, Anderson B, Tsui J, Meshesha LZ, Dossabhoy S, Stein M. Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial. JAMA Intern Med. 2014;174:1369–76. doi:10.1001/jamainternmed.2014.2556.
   PubMed Web of Science ®Google Scholar
• Samples H, Williams AR, Olfson M, Crystal S. Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of medicaid enrollees. J Subst Abuse Treat. 2018;95:9–17. doi:10.1016/j.jsat.2018.09.001.
   PubMed Web of Science ®Google Scholar
• Tkacz J, Volpicelli J, Un H, Ruetsch C. Relationship between buprenorphine adherence and health service utilization and costs among opioid dependent patients. J Subst Abuse Treat. 2014;46:456–62. doi:10.1016/j.jsat.2013.10.014.
   PubMed Web of Science ®Google Scholar
• Ronquest NA, Willson TM, Montejano LB, Nadipelli VR, Wollschlaeger BA. Relationship between buprenorphine adherence and relapse, health care utilization and costs in privately and publicly insured patients with opioid use disorder. Subst Abuse Rehabil. 2018;9:59. doi:10.2147/SAR.S150253.
   PubMed Web of Science ®Google Scholar
• Meinhofer A, Williams AR, Johnson P, Schackman BR, Bao Y. Prescribing decisions at buprenorphine treatment initiation: do they matter for treatment discontinuation and adverse opioid-related events? J Subst Abuse Treat. 2019;105:37–43. doi:10.1016/j.jsat.2019.07.010.
   PubMed Web of Science ®Google Scholar
• Weiss RD, Potter JS, Griffin ML, Provost SE, Fitzmaurice GM, McDermott KA, Srisarajivakul EN, Dodd DR, Dreifuss JA, McHugh RK. Long-Term outcomes from the national drug abuse treatment clinical trials network prescription opioid addiction treatment study. Drug Alcohol Depend. 2015;150:112–19.
   PubMed Web of Science ®Google Scholar
• Tibshirani R, Walther G, Hastie T. Estimating the number of clusters in a data set via the gap statistic. J Royal Stat Soc Ser B (Stat Methodol). 2001;63:411–23. doi:10.1111/1467-9868.00293.
   Google Scholar
• Ho D, Imai K, King G, Stuart E, Greifer N. Package ‘MatchIt’; 2021 [accessed 2021 May 12]. https://cran.r-project.org/web/packages/MatchIt/MatchIt.pdf
   Google Scholar
• Zhang Z, Kim HJ, Lonjon G, Zhu Y, written on behalf of AMEB-DCTCG. Balance diagnostics after propensity score matching. Ann Transl Med. 2019; 7:16.
   PubMed Web of Science ®Google Scholar
• Dakwar E, Kleber HD. Naltrexone-Facilitated buprenorphine discontinuation: a feasibility trial. J Subst Abuse Treat. 2015;53:60–63. doi:10.1016/j.jsat.2015.01.004.
   PubMed Web of Science ®Google Scholar
• Brown S-E, Altice FL. Self-Management of buprenorphine/naloxone among online discussion board users. Subst Use Misuse. 2014;49:1017–24. doi:10.3109/10826084.2014.888449.
   PubMed Web of Science ®Google Scholar